Biggest Challenge –Although the industry is at the forefront of innovation, consumer, patient and client adoption remains the biggest industry challenge (37 percent) followed by regulation (34 percent). Greatest Impact on Investments –Thirty-four percent of survey respondents say the success of existing technologies gaining traction will have the greatest impact on investment in the sector next year. Despite uncertainty, the upcoming US Presidential election was seen as least influential factor impacting investment in the industry (7 percent). Most Promising Technology – Survey respondents say big data (46 percent) and artificial intelligence (35 percent) are the technical innovations that will have the greatest impact on healthtech in 2017. Biggest Growth Sector – Healthcare delivery/IT is cited as most likely to experience growth in the coming year (45 percent), ahead of more consumer-focused products including mobile health apps (8 percent) and wearables (7 percent).

According to a survey of 122 founders, executives and investors in health-tech companies released today by Silicon Valley Bank, big data and artificial intelligence will have the greatest impact on the industry in the year ahead. Healthcare delivery and healthcare IT also promise the most growth in 2017. "Big data has been integral to our work at Celmatix. It has empowered physicians to be able to counsel women about their chances of having a baby, based on their relevant personal metrics, and not just their age," said Dr. Piraye Yurttas Beim, CEO at Celmatix. "It's an exciting time to be in a field where the pace of innovation continues to increase as both physicians and patients realize the potential of big data and personalized medicine."

According to a survey of 122 founders, executives and investors in health-tech companies released today by Silicon Valley Bank, big data and artificial intelligence will have the greatest impact on the industry in the year ahead. Healthcare delivery and healthcare IT also promise the most growth in 2017. "Big data has been integral to our work at Celmatix. It has empowered physicians to be able to counsel women about their chances of having a baby, based on their relevant personal metrics, and not just their age," said Dr. Piraye Yurttas Beim, CEO at Celmatix. "It's an exciting time to be in a field where the pace of innovation continues to increase as both physicians and patients realize the potential of big data and personalized medicine."